CEACAM5 and pancreatic neoplasm: Several clinical trials are ongoing to better understand the safety, adverse events and potential effectiveness of CEA-targeted CAR T cells in liver metastases (NCT02850536), colorectal cancer (NCT02959151), and CEA positive cancer, including gastric cancer, lung cancer, pancreatic cancer, breast cancer and colorectal cancer (NCT02349724).